A trial of the synthetic malaria vaccine SPf66 in Tanzania: rationale and design

P L Alonso; M Tanner; T Smith; R J Hayes; J A Schellenberg; M C Lopez; I Bastos de Azevedo; C Menendez; E Lyimo; N Weiss

doi:10.1016/0264-410x(94)90058-2

A trial of the synthetic malaria vaccine SPf66 in Tanzania: rationale and design

Vaccine. 1994 Feb;12(2):181-6. doi: 10.1016/0264-410x(94)90058-2.

Authors

P L Alonso¹, M Tanner, T Smith, R J Hayes, J A Schellenberg, M C Lopez, I Bastos de Azevedo, C Menendez, E Lyimo, N Weiss, et al.

Affiliation

¹ Epidemiology Research Unit, Fundacio per a la Recerca Biomedica, Barcelona, Spain.

PMID: 8147101
DOI: 10.1016/0264-410x(94)90058-2

Abstract

The development of a safe, affordable and effective malaria vaccine to form part of control schemes in malaria endemic countries is a priority for researchers and public health officials. SPf66 is the first malaria vaccine to have shown partial protection against natural challenge in a phase III trial carried out in a hypoendemic area of Colombia. This paper describes the rationale and design of the first field trial of SPf66 outside South America, and the first to be conducted in an area of high perennial transmission.

Publication types

Clinical Trial
Clinical Trial, Phase III
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Animals
Child, Preschool
Ethics, Medical
Humans
Infant
Malaria Vaccines* / adverse effects
Malaria Vaccines* / immunology
Malaria, Falciparum / prevention & control*
Male
Plasmodium falciparum / immunology
Protozoan Proteins / immunology*
Protozoan Vaccines
Recombinant Proteins*
Safety
Tanzania
Vaccines, Synthetic / adverse effects
Vaccines, Synthetic / immunology
Vaccines, Synthetic / pharmacology

Substances

Malaria Vaccines
Protozoan Proteins
Protozoan Vaccines
Recombinant Proteins
SPf66 protein, Plasmodium
Vaccines, Synthetic